Then, a company named Regeneron announced they would buy the company, and would “prioritize [consumer data's] privacy, security and ethical use." Now there's been another twist: That company was outbid just before the sale closed,

Anne Wojcicki is poised to regain control of genetics testing company 23andMe, which she cofounded and led until earlier this year, after agreeing to put much of her personal fortune on the line. Why it matters: This is the same person that 23andMe customers originally trusted with their personal data,

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.